Clinical Trial

Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, phase II, prospective study. The main purpose of study is to evaluate the efficacy and safety of Glofitamab plus Polatuzumab vedotin and Zuberitamab in patients with newly diagnosed diffuse large B-cell lymphoma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-13.
Trial Details
NCT Number NCT07231250
Lead Sponsor Li Zhiming
Conditions DLBCL - Diffuse Large B Cell Lymphoma, Chemo-free Therapy, Bispecific Antibody
Enrollment 40 participants
Start Date 2026-01-15
Primary Completion 2026-09-15 (estimated)
Study Completion 2028-09-15 (estimated)
Updated on ClinicalTrials.gov 2025-11-19